Under federal law, marijuana is currently a Schedule I substance, meaning the government considers it a highly addictive drug with no legitimate medical use. But the Trump administration is now asking for public comment on whether marijuana should be reclassified under international drug control treaties in which the U.S. is a party. 
In addition to being classified as a Schedule I substance in the U.S., marijuana is also considered a Schedule I drug under global agreements. That means that countries which have signed onto drug treaties are not supposed to legalize it. 
But the United Nations World Health Organization is preparing to launch a review of the current international classification for marijuana. This includes review of THC, the psychoactive cannabinoid in marijuana, cannabidiol (CBD), and other related compounds and preparations. The organization is seeking input from member nations.
As a result, the U.S. Food and Drug Administration (FDA) wants “interested persons” to submit comments aimed at informing the U.S.’s position on the subject before it weighs in with the U.N.
Specifically, the agency is asking people to give their views on the ‘abuse potential, actual abuse, medical usefulness, trafficking and impact of scheduling changes on availability for medical use of marijuana and its compounds,’ according to a notice in the Federal Register, published April 2, 2018.
Then, in June, the WHO’s Expert Committee on Drug Dependence will meet to discuss cannabis’ classification and develop pre-review recommendations for the U.N. secretary-general about conducting a more comprehensive analysis.
Depending on the results, cannabis could be rescheduled internationally, which would likely prompt the U.S. to change marijuana’s status.
We KNOW that Marijuana can be Beneficial
The WHO has already said that CBD appears to be safe, non-addictive, and well-tolerated in both humans and animals, with many proven medicinal benefits. CBD is not currently listed under international schedules, but is a Schedule I substance in the U.S. (Various individual states have their own laws concerning the legality of CBD oil.)
The committee said of CBD:
“There is no evidence of…any public health related problems associated with the use of pure CBD.”
Shockingly, the FDA noted in a press release that the federal government has not formally reviewed marijuana’s Schedule I status since it was classified as such in 1961. 
The FDA will start taking public comments beginning April 9, 2018, and will stop taking them on April 23.